A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Status:
Terminated
Trial end date:
2019-04-08
Target enrollment:
Participant gender:
Summary
This research trial is studying a drug called alectinib as a possible treatment for non-small
cell lung cancer (NSCLC) with specific genetic alterations known as ALK or RET
rearrangements, and thyroid cancer with RET rearrangements.